Clinical Trial Update: Oral LAT8881 in Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for oral LAT8881 in neuropathic pain conditions has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy
• Neuropathic Pain
• Postherpetic Neuralgia

Drugs mentioned

• LAT8881

Snippet

Sponsor: Lateral Pharma Pty Ltd | Conditions: Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN) | Phase 2 | Status: COMPLETED | Results posted: 2021-04-23